- Home
- TLSA vs ADAG Comparison
TLSA vs ADAG Comparison
Compare TLSA & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLSA | ADAG |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 84.8M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TLSA | ADAG |
|---|---|---|
| Price | $1.49 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 414.9K | 53.1K |
| Earning Date | 01-01-0001 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $1.30 |
| 52 Week High | $2.60 | $3.16 |
Technical Indicators
Market Signals| Indicator | TLSA | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 48.48 |
| Support Level | $1.45 | $1.76 |
| Resistance Level | $1.62 | $1.93 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 35.58 | 48.94 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.